Daniel Citterio received his Doctoral degree in Natural Sciences from the Swiss Federal Institute of Technology (ETH) in Zurich (Switzerland) in 1998. From 1998-2002, he was a postdoctoral researcher at Keio University with Prof. Koji Suzuki. Upon return to Switzerland, he worked as a researcher at ETH, before joining Ciba Specialty Chemicals Inc.. In 2006, he moved back to Keio University, where he became a tenured Associate Professor in 2009 and Professor in 2014. In 2016, he has been admitted as a Fellow of the Royal Society of Chemistry (RSC). He serves as a co-Editor-in-Chief of the journal Sensors and Actuators B: Chemical, as well as on the Editorial Advisory Board of ACS Sensors. In 2022, he has been awarded the Chemical Society of Japan Award for Creative Work. His research is focusing on the development of chemical sensors and biosensors. More recently, his research team is strongly engaged in the development of microfluidic paper-based analytical devices (µPADs) for low-cost point-of-need applications.
CRISPR/Cas Assays Fully Integrated Into Paper-based Platforms
Thursday, 7 November 2024 at 14:00
Add to Calendar ▼2024-11-07 14:00:002024-11-07 15:00:00Europe/LondonCRISPR/Cas Assays Fully Integrated Into Paper-based PlatformsLab-on-a-Chip, Microfluidics, and Organ-on-a-Chip Asia 2024 in Tokyo, JapanTokyo, JapanSELECTBIOenquiries@selectbiosciences.com
There has been a rapid growth in the development of analytical assays based on the CRISPR/Cas nuclease enzyme system. On the other hand, paper-based analytical devices (PADs) have gained a lot of attention as platforms potentially suitable for point-of-care testing (POCT) applications. Despite both approaches having multiple advantages, their combination into fully integrated POCT devices has rarely been reported. In most combinations of CRISPR/Cas technology with PADs, the latter is simply used for a final signal detection step, while otherwise the assay is performed in the liquid phase in tubes. This presentation will be showing that the two technologies can be successfully combined into fully integrated devices, and that the CRISPR/Cas system is suitable for on-device storage, a prerequisite for future POCT applications. As a proof-of-concept for a practical assay of clinical relevance, a PAD for the highly sensitive quantitative determination of the hepatitis B virus surface antigen (HBsAg) is presented. The developed assay achieved a limit of detection in the order of 30 pg/mL in undiluted spiked porcine blood plasma samples, and was also applied to undiluted spiked whole blood with signal readout on a portable smartphone setup. The presented results demonstrate that the CRISPR/Cas system is a promising tool for use in the development of highly sensitive paper-based assays.
Add to Calendar ▼2024-11-07 00:00:002024-11-08 00:00:00Europe/LondonLab-on-a-Chip, Microfluidics, and Organ-on-a-Chip Asia 2024Lab-on-a-Chip, Microfluidics, and Organ-on-a-Chip Asia 2024 in Tokyo, JapanTokyo, JapanSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2024-11-07 14:00:002024-11-07 15:00:00Europe/LondonCRISPR/Cas Assays Fully Integrated Into Paper-based PlatformsLab-on-a-Chip, Microfluidics, and Organ-on-a-Chip Asia 2024 in Tokyo, JapanTokyo, JapanSELECTBIOenquiries@selectbiosciences.com
